Press Release

Northbrook, Ill., April 17, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA.   At AACR 2026, a trials-in-progress poster will be presented by Endevica…

Northbrook, Ill., March 31, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Tony Mitchell as Chief Financial Officer. Mr. Mitchell brings more than two decades of accounting and finance leadership experience spanning…

Novel dual melanocortin-3 and -4 receptor (MC3R/MC4R) agonists with improved potency, selectivity, central exposure and cardiac safety profiles may unlock broad use in general obesity Northbrook, Ill., March 25, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer…

Kalohexis’ lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists Northbrook,…

NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ — Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company’s research demonstrates that co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss, unlocking the melanocortin system as a differentiated mechanism…

NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ — Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent weight loss in cancer patients undergoing chemotherapy. The trial, being conducted in partnership with WuXi Clinical, will…

NORTHBROOK, Ill., Dec. 20, 2024 /PRNewswire/ A peptide called TCMCB07 will be administered to patients who are diagnosed with stage 4 metastatic colorectal cancer and will undergo chemotherapy. Endevica Bio, a privately held company developing first-in-class peptide drug candidates, today announced the start of a Phase 2 clinical trial of its experimental drug TCMCB07 (B07) to prevent…

NORTHBROOK, Ill., Nov. 12, 2024 /PRNewswire/ The Journal of Clinical Investigation (JCI) publishes results of a Melanocortin-4 receptor antagonist, TCMCBO7 Endevica Bio’s experimental peptide to prevent weight loss associated with cachexia improved the appetite and preserved lean mass and fat mass in rodent models of cancer chemotherapy, according to data from a preclinical study published today in…

NORTHBROOK, Ill., April 23, 2024 /PRNewswire/ Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study. This latest research solidifies Endevica Bio’s status as a world leader in the scientific understanding of the central melanocortin system. The company’s proof-of-concept MC4R agonist compound A07D…